Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
51 NC counties are under alert, including Johnston and Chatham counties.
Closings
13 closings/delays reported.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Supernus Pharm
(NQ:
SUPN
)
30.75
-0.02 (-0.06%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Supernus Pharm
< Previous
1
2
3
4
Next >
Supernus Announces First Quarter 2023 Financial Results
May 09, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For May 9, 2023
May 09, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.
Via
Benzinga
Supernus Pharmaceuticals's Earnings: A Preview
May 08, 2023
Via
Benzinga
FDA Rejects Supernus Pharma's Minimally Invasive Parkinson's Therapy
October 10, 2022
Via
Benzinga
FDA Approves Expanded Use Of Supernus' Viloxazine In Adult ADHD Patients
May 02, 2022
Via
Benzinga
Something Happened In Biotech Last Week
May 08, 2023
Biotech stocks were more constructive last week with some sharp moves up.
Via
Talk Markets
Supernus to Present at the Bank of America 2023 Health Care Conference
May 02, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023
April 25, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Repayment of Convertible Notes
April 03, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus to Participate in Two Upcoming Investor Conferences
March 08, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus to Present at the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Enters Into $150 Million Credit Facility
February 14, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For February 28, 2023
February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.
Via
Benzinga
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023
February 09, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
February 05, 2023
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?
Via
Talk Markets
Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
December 01, 2022
During Thursday's session, 108 stocks hit new 52-week highs.
Via
Benzinga
Supernus to Present at Two November Healthcare Conferences
November 08, 2022
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Third Quarter 2022 Financial Results
November 08, 2022
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022
October 25, 2022
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Provides Regulatory Update on SPN-830
October 10, 2022
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Top Medical Specialties Stocks: Trading Opportunities For Next Week - Sunday, Oct. 2
October 02, 2022
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Here is a closer look at some medical stock opportunities...
Via
Talk Markets
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
October 02, 2022
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...
Via
Benzinga
Stocks That Made New Highs On Friday, Aug. 19
August 21, 2022
On Friday, in spite of the stock market being down, there were several stocks that actually made new highs.
Via
Talk Markets
Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
July 25, 2022
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
May 01, 2022
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a...
Via
Benzinga
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
April 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
April 24, 2022
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...
Via
Benzinga
Looking Into Supernus Pharmaceuticals's Return On Invested Capital
April 14, 2022
According to Benzinga Pro data Supernus Pharmaceuticals (NASDAQ:SUPN) posted a 88.67% decrease in earnings from Q3. Sales, however, increased by 7.13% over the previous quarter to $159.05 million.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.